Compare BridgeBio Pharma Inc (BBIO) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Standard Lithium Ltd — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Standard Lithium Ltd trades at $2.45 (market cap $624.94M). The key difference: BridgeBio Pharma Inc is far larger — about 26.6× Standard Lithium Ltd's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals.
| BBIO | SLI | |
|---|---|---|
Market Cap | $16.61B | $624.94M |
Sector | Health | Basic Materials |
52-Week High | $90.17 | $5.65 |
52-Week Low | $47.29 | $1.93 |
Enterprise Value | $18.16B | $484.14M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Standard Lithium (SLI) trades at $2.37, up 4.41% with a bullish technical signal despite mixed earnings performance. The company maintains 100% analyst buy ratings and strong institutional interest, including Amundi's 64.9% stake increase. Recent developments show progress toward final investment decision for the South West Arkansas lithium project, supported by a $225M DOE grant and key construction contracts. Financials reflect development-stage challenges with negative profitability metrics but substantial financing activity.
Outlook remains constructive as SLI transitions toward production with major project de-risking, though execution risks and negative cash flows warrant monitoring. The stock presents growth potential in lithium sector expansion but faces operational and funding challenges during development phase. Current valuation at 1.72x book value reflects market optimism about project economics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
